Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | A Study of CK-1827452 Infusion in Stable Heart Failure | Completed | Heart Failure | Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug - CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, CK-1827452, Placebo, Placebo, CK-1827452, Placebo, CK-1827452, CK-1827452, CK-1827452, CK-1827452 | Cytokinetics, Industry | 18 Years - N/A | Phase 2 | Interventional | This study will assess the safety, tolerability, and pharmacodynamics of CK-1827452 infusion in patients with stable heart failure. | ||
Clinicaltrials.gov | The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure | Terminated | Heart Failure, Renal Failure | Drug, Drug - Carperitide heart failure therapy, Standard heart failure therapy | Nara Medical University, Other | 20 Years - 80 Years | Phase 4 | Interventional | Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan. However, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. The purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy. | ||
|
Clinicaltrials.gov | Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure | Terminated | Mitral Valve Insufficiency, Heart Failure | Procedure, Drug - Surgical mitral valvuloplasty with placement of annular ring (SMVR), Optimal medical therapy (OMT) | Duke University, National Heart, Lung, and Blood Institute (NHLBI), Heart Failure Clinical Research Network, Other, NIH, Other | 18 Years - N/A | Phase 3 | Interventional | Mitral regurgitation (MR), also known as mitral insufficiency, is a condition in which the heart's mitral valve, located between two of the heart's main chambers, does not firmly shut, allowing blood to leak backwards within the heart. Improper functioning of the mitral valve disrupts the proper flow of blood through the body, resulting in shortness of breath and fatigue. When mild, MR may not pose a significant danger to a person's health, but severe MR may be associated with serious complications, such as heart failure, irregular heart rhythm, and high blood pressure. Although there are treatments for MR, including medication and surgery, more information is needed on the effectiveness of these treatments in people with significant MR. This study will compare the safety and effectiveness of corrective surgery added to optimal medical treatment (OMT) versus OMT alone in treating people with significant MR caused by an enlarged heart. | ||
|
Clinicaltrials.gov | Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure | Completed | Heart Failure | Device - SphygmoCor | Mayo Clinic, AtCor Medical, Inc., Other, Industry | 18 Years - N/A | N/A | Interventional | Heart failure (HF) is the leading cause of hospitalization among Americans over the age of 65 years, affecting greater than 5 million in the U.S. alone. Significant improvements in morbidity and mortality have been achieved through the use of medications that antagonize adverse neurohormonal signaling pathways, particularly therapies that reduce left ventricular (LV) afterload. Vascular stiffness increases with aging, contributing to the increase in cardiac load. One important repercussion of such stiffening is an increase in pulse wave velocity. As the incident pressure wave generated by cardiac ejection encounters zones of impedance mismatch (such as arterial bifurcations), part of the wave is reflected backward, summing with the incident wave, increasing central blood pressure (CBP). With normal aging, hypertension, and heart failure, increased wave velocity causes the reflected wave to reach the heart earlier, in mid to late systole, considerably increasing late-systolic load, impairing cardiac ejection, and diastolic relaxation in the ensuing cardiac cycle. The magnitude of this reflected pressure wave can be quantified by the augmentation index (AIx). The use of vasoactive agents which antagonize this increase in late systolic load (and AIx) may prove useful in the treatment of heart failure, by facilitating cardiac ejection during late systole when reflected pressure waves predominate. However, it has never been conclusively shown in humans that CBP-targeted therapy is useful in the management of HF. LV afterload, measured centrally in the ascending aorta, may differ considerably from brachial cuff-measured pressure, and has traditionally required invasive hemodynamic assessment to determine, limiting the applicability of techniques targeting CBP and late-systolic load. Recently, a novel, hand-held tonometer (SphygmoCor, Atcor Medical) has been developed for the noninvasive assessment of CBP. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure. This device has received FDA approval for clinical use in the assessment of central pressures. However, it remains unknown whether knowledge of CBP and late-systolic load (AIx) confers any clinically-significant incremental benefit in the management of patients with heart failure. The primary objective of the proposed investigation will be to determine if this assessment might have such a role. | ||
|
Clinicaltrials.gov | Jarvik 2000 Heart as a Bridge to Cardiac Transplantation - Pivotal Trial | Completed | Heart Failure | Device - The Jarvik 2000 Ventricular Assist System | Jarvik Heart, Inc., Industry | 18 Years - N/A | Phase 2/Phase 3 | Interventional | The purpose of the study is to determine the safety and effectiveness of the Jarvik 2000 Heart as a bridge to heart transplantation in end-stage heart failure patients who are approved heart transplant candidates. | ||
|
Clinicaltrials.gov | Assessment of Cardiac Functional Reserve in Heart Failure With Preserved Ejection Fraction (HF-PEF) | Completed | Heart Failure | University of Wisconsin, Madison, Other | 18 Years - N/A | Observational | This study will compare the ability of the heart to increase its contractile performance during stress in patients with a history of heart failure without systolic dysfunction and in controls. | ||||
|
Clinicaltrials.gov | Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure | Terminated | Heart Failure, Dilated Cardiomyopathy | Drug - clenbuterol | Francis D. Pagani, Georgetown University, Montefiore Medical Center, Northwestern University, Ohio State University, Texas Heart Institute, University of Minnesota, University of Pennsylvania, Thoratec Corporation, Other, Other, Other, Other, Other, Other, Other, Other, Industry | 18 Years - N/A | Phase 1 | Interventional | The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function. | ||
|
Clinicaltrials.gov | The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment | Completed | Heart Failure | Drug - phenylephrine | University of Utah, Other | 18 Years - 85 Years | N/A | Interventional | There is now strong evidence from clinical trials that carvedilol therapy in heart failure is superior to therapy with metoprolol. Not only does carvedilol have superior effects on lipid profiles, insulin sensitivity, renal blood flow, and reversal of pathologic remodeling but also its use is associated with fewer deaths compared to metoprolol. These facts make it important to carefully define how metoprolol and carvedilol are pharmacologically different. One potential difference is α1-AR antagonism. If we demonstrate that these α1-AR effects are preserved with chronic therapy, then α1-AR blockade may have an important role in carvedilol favorably altering the natural history of heart failure. On the other hand, if we demonstrate that tolerance to the α1-AR blockade effect of carvedilol decreases with time, then it would be unlikely that this pharmacologic property contributes to the efficacy of carvedilol. In such a case other pharmacologic properties, such as antioxidant activity, would appear to be important. These results will help guide future studies into CHF and AR blockade. | ||
|
Clinicaltrials.gov | Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device | Completed | Heart Failure, Cardiomyopathies | Device - EXCOR Pediatric | Berlin Heart, Inc, Industry | N/A - 16 Years | N/A | Interventional | The purpose of the study is to determine whether use of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device for bridge-to-transplant is associated with a reasonable assurance of safety and probable benefit such that the EXCOR® Pediatric merits approval by the Food and Drug Administration under a Humanitarian Device Exception (HDE). | ||
|
Clinicaltrials.gov | Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant | Unknown status | Acromegaly, Heart Failure, Hypertrophy, Left Ventricular | Drug - pegvisomant | University of Wuerzburg, Pfizer, Other, Industry | 18 Years - N/A | Phase 4 | Interventional | The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year. | ||
|
Clinicaltrials.gov | Randomised Trial of Health Coaching in Secondary Prevention of Diabetes and Heart Disease | Unknown status | Diabetes Mellitus, Type 2, Heart Failure, Coronary Disease | Behavioral - Health coaching | Paijat-Hame Hospital District, Sitra, the Finnish Innovation Fund, Pfizer, Tampere University, Other, Other, Industry, Other | 45 Years - N/A | Phase 3 | Interventional | A randomised trial with individual patients as units of observation will be carried out. Health coaching is used to modify health behaviour and thus improve disease control and health status, as well as use of health care services. A personal health coach is assigned to each patient and they are in weekly contact through telephone. The intervention lasts for 12 months. No intervention is offered to the patients in the control arm. | ||
|
Clinicaltrials.gov | Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) | Completed | Heart Failure | Device - HeartPOD™ System | Abbott Medical Devices, Industry | 18 Years - 85 Years | N/A | Interventional | This study is a feasibility study of the HeartPOD™ Heart Failure Management System with DynamicRx® (HeartPOD system) in patients with severe chronic congestive heart failure. The device being studied in this trial monitors heart function and alerts the patient and physician of necessary changes to medication. The study will assess the safety, reliability, and preliminary efficacy of the HeartPOD™ system. | ||
|
Clinicaltrials.gov | Effects of Chocolate in Patients With Chronic Heart Failure | Completed | Heart Failure | Dietary Supplement, Dietary Supplement - Nestlé Noir intense 40 grx2, Nestlé Placebo Chocolate 40 grx2 | University of Zurich, Other | 30 Years - 80 Years | N/A | Interventional | The aim of the present study is to investigate whether in patients with chronic heart failure endothelial dysfunction and baroreceptor function is altered by ingestion of a flavonoid-rich dark chocolate in comparison to placebo chocolate (Nestlé Placebo Chocolate) on top of standard medication. Moreover, we will evaluate the effect of chocolate on oxidative stress, platelet adhesion as well as systemic inflammatory response such as C-reactive protein and pro-inflammatory cytokines in patients with chronic heart failure. | ||
|
Clinicaltrials.gov | Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure | Unknown status | Heart Failure, Renal Insufficiency | Drug, Drug - Levosimendan in addition to standard therapy, spironolactone, beta-blockers,ecc | University of Roma La Sapienza, Other | N/A - N/A | Phase 4 | Interventional | The purpose of this study is to evaluate the effect of levosimendan infusion, in addition to standard therapy,on renal function in patients with Acute Heart Failure,compared with standard therapy alone. | ||
|
Clinicaltrials.gov | The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy | Unknown status | Muscular Dystrophy, Dilated Cardiomyopathy, Heart Failure | Baylor College of Medicine, Other | 1 Month - 65 Years | Observational | This study will have significant impact on muscular dystrophy patients as it promotes early screening for heart disease. With early identification, beneficial medical therapy can be started sooner, resulting in restoring and maintaining normal heart function. This is critical to the survival of these patients. We have reported previously that heart failure in all patients may have common mechanisms, the "final common pathway". Heart failure is a significant health problem with 5 million people in the US carrying the diagnosis and accounting for 12-15 million office visits and 6.5 million hospital days per year. The number of deaths from heart failure continues to increase. The data from this study could impact patients worldwide with heart failure by offering new insight into an ever-growing disease population and lead to significant changes in how they are currently treated. | ||||
|
Clinicaltrials.gov | The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure | Completed | Heart Failure | Drug, Drug - ALT-711, Placebo | Synvista Therapeutics, Inc, Industry | 19 Years - N/A | Phase 2 | Interventional | Several lines of evidence have suggested that Advanced Glycation End-products (AGEs) play a role in the development and progression of heart failure. The AGE-crosslink breaker Alagebrium (ALT-711) improved cardiac function and symptoms in experimental and small human heart failure studies. These results have not yet been confirmed in a randomized controlled clinical trial. | ||
|
Clinicaltrials.gov | Growth Hormone Deficiency in Chronic Heart Failure: an Observational Study | Completed | Ischemic Heart Disease, Cardiomyopathy, Heart Failure, Growth Hormone Deficiency | Federico II University, Other | 18 Years - 80 Years | Observational | Aim of this study is to define the possible detrimental effect of a lack of growth hormone, on the well-being and life expectation of patients affected by heart failure. | ||||
|
Clinicaltrials.gov | Cardiac Resynchronization Therapy Defibrillator Based Impedance Monitoring Study | Completed | Heart Failure | Device - Transthoracic Impedance | Abbott Medical Devices, Industry | 18 Years - N/A | N/A | Interventional | The intent of this feasibility study is to collect and analyze intra-thoracic impedance measurements from a CRT-D device in a heart failure population. | ||
|
Clinicaltrials.gov | Clinical Usefulness and Efficacy of Intrathoracic Impedance Monitoring Using the OptiVol Patient Alert(TM) | Completed | Heart Failure | Catharina Ziekenhuis Eindhoven, Medtronic, Other, Industry | 18 Years - N/A | Observational | In this study we investigate the clinical value and efficacy of OptiVol (TM) impedance measurements by Medtronic (R) ICD's. We aim to determine sensitivity and positive predictive value for detecting heart failure. We also investigate if left ventricular filling pattern measured by echocardiography and/or brain natriuretic peptide (BNP) level can be used to improve the positive predictive value of the Optivol alert | ||||
|
Clinicaltrials.gov | Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial) | Terminated | Heart Failure | Device - Programming (CRT-D, ICD OptiVol® and Cardiac Compass® ) | Medtronic Bakken Research Center, Industry | 18 Years - N/A | Phase 4 | Interventional | The DOT-HF trial is an international, prospective, multi-center, randomized, controlled trial. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
